Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Chorionic gonadotropin oral

Drug Profile

Chorionic gonadotropin oral

Alternative Names: BTL-cg; HP 4; LDI-100; ML-04; ML-04A

Latest Information Update: 22 Jan 2007

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Milkhaus Laboratory
  • Class Infertility therapies; Peptide hormones; Pituitary gonadotropins; Placental hormones
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Benign prostatic hyperplasia; Myelodysplastic syndromes; Prostatitis

Most Recent Events

  • 12 Nov 2003 A study has been added to the adverse events and Mens Health therapeutic trials sections
  • 30 Jul 2003 Milkhaus has completed enrolment in a phase IIb trial for Benign prostatic hyperplasia in the US
  • 02 Apr 2003 Data from a media release have been added to the adverse events and Mens Health therapeutic trials sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top